Affected market: Pharmaceuticals
On the basis of the information available to it, the Office of Fair
Trading has decided that the proposed acquisition of Biogen Inc by IDEC
Pharmaceuticals Corp does not qualify for investigation under the
mergers provisions of the Enterprise Act 2002, because neither the UK
turnover test nor the share of supply test in section 23 of the Act is
met. A relevant merger situation has, therefore, not been created.